Trial Profile
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Gallium 68-DOTATATE (Primary) ; Fludeoxyglucose F-18
- Indications Head and neck cancer; Squamous cell cancer
- Focus Diagnostic use; Proof of concept
- 23 Apr 2019 Planned End Date changed from 1 Jul 2019 to 31 Jul 2019.
- 23 Apr 2019 Planned primary completion date changed from 30 Mar 2019 to 30 Jul 2019.
- 01 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 30 Mar 2019.